[go: up one dir, main page]

AR002011A1 - Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas. - Google Patents

Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas.

Info

Publication number
AR002011A1
AR002011A1 ARP950100629A AR10062995A AR002011A1 AR 002011 A1 AR002011 A1 AR 002011A1 AR P950100629 A ARP950100629 A AR P950100629A AR 10062995 A AR10062995 A AR 10062995A AR 002011 A1 AR002011 A1 AR 002011A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
alkoxy
piperidine
pharmaceutical compositions
Prior art date
Application number
ARP950100629A
Other languages
English (en)
Inventor
Mary Gaster Laramie
Francis David King
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426029.6A external-priority patent/GB9426029D0/en
Priority claimed from GBGB9512920.1A external-priority patent/GB9512920D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR002011A1 publication Critical patent/AR002011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen nuevos derivados de piperidina de fórmula (I), proceso para su preparación, composiciones farmacéuticas que las contienen y su uso comomedicamentos en donde R1 es hidrógeno, halógeno, alquilo, ciclo-alquilo, alquil-CO, alcoxi, hidroxi, hidroxialquilo, hidroxialcoxi, alcoxi-alcoxi,acilo, nitro, trifluorometilo, ciano, SR9, SOR9, SO2R9, SO2NR10R11, CO2R10, NR10SO2R11, CONR10R11, CO2NR10R11, CONR10(CH2)pCO2R11, (CH2)pNR10R11,(CH2)pCONR10R11, (CH2)pNR10COR11, (CH2)pCO2-alquilo, CO2-(CH2)pOR10, CONHNR10R11, NR10R11, NR10CO2R11, NR10CO(CH2)pNR10R11, NR10CONR10R11,CR10=NOR11, CNR10=NOR11, en donde R9, R10 y R11 son independientemente hidrógeno o alquilo y p es 1 a 4; o R1 es un anillo heterocíclico de 5a 7miembros opcionalmente sustituido conteniendo 1 a 4 heteroátomos seleccionados de oxígeno, nitrógeno y azufre; R2 y R3 son hidrógeno, halógeno, alquilo,cicloalquilo, cicloalquenilo, alcoxi, hidroxialquilo, alcoxialquilo, acilo, arilo, aciloxi, hidroxi, nitro, trifluorometilo, ciano, CO2R10, CONR10R11,NR10R11, donde R10 y R11 son hidrógeno o alquilo; R4, R5 y R6 son hidrógeno o alquilo; A es (CR13R14)q donde q es 2, 3 ó 4 y R13 y R14 son hidrógeno oalquilo o A es (CR13R14)r-D, donde r es 0, 1, 2, ó 3 y D es oxígeno, azufre o CR13=CR14, B es oxígeno, CR15R16 o NR17 donde R15, R16 y R17 son hidrógeno oalquilo o B es S(O)b donde b es 0, 1 ó 2; m es 1, 2 ó 3 y n es 1, 2 ó 3.
ARP950100629A 1994-12-22 1995-12-19 Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas. AR002011A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426029.6A GB9426029D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9512920.1A GB9512920D0 (en) 1995-06-24 1995-06-24 Novel compounds

Publications (1)

Publication Number Publication Date
AR002011A1 true AR002011A1 (es) 1998-01-07

Family

ID=26306239

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100629A AR002011A1 (es) 1994-12-22 1995-12-19 Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas.

Country Status (27)

Country Link
US (1) US5972951A (es)
EP (1) EP0799226B1 (es)
JP (1) JPH10510821A (es)
CN (1) CN1175256A (es)
AP (1) AP757A (es)
AR (1) AR002011A1 (es)
AT (1) ATE199085T1 (es)
AU (1) AU697361B2 (es)
BG (1) BG61977B1 (es)
BR (1) BR9510419A (es)
CA (1) CA2208244A1 (es)
CZ (1) CZ192397A3 (es)
DE (1) DE69520075T2 (es)
DZ (1) DZ1957A1 (es)
ES (1) ES2153907T3 (es)
FI (1) FI972583A7 (es)
HU (1) HUT77650A (es)
IL (1) IL116486A0 (es)
MA (1) MA23753A1 (es)
MX (1) MX9704777A (es)
NO (1) NO972910L (es)
NZ (1) NZ298036A (es)
OA (1) OA10610A (es)
PL (1) PL321048A1 (es)
SK (1) SK80297A3 (es)
TR (1) TR199501597A2 (es)
WO (1) WO1996019477A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519033D0 (en) * 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
US6166034A (en) * 1995-11-08 2000-12-26 Smithkline Beecham P. L. C Spiro piperidine derivatives as 5HT1D receptor antagonists
GB9522845D0 (en) * 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
WO1997019070A1 (en) * 1995-11-22 1997-05-29 Smithkline Beecham Plc Tricyclic spiro compounds as 5ht1d receptor antagonists
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606396D0 (en) * 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761069A1 (fr) * 1997-03-20 1998-09-25 Pf Medicament Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments
AU6123699A (en) * 1998-10-16 2000-05-08 Takeda Chemical Industries Ltd. Nitrogenous fused heterocycle compounds, process for the preparation thereof andagents containing the same
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
TWI454465B (zh) * 2003-06-03 2014-10-01 Melinta Therapeutics Inc 聯芳基雜環化合物及製法及其用途
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
CN101346336B (zh) 2005-12-26 2013-02-27 日产化学工业株式会社 1,3-二(取代苯基)-3-取代-2-丙烯-1-酮化合物和其盐
SG183054A1 (en) 2007-04-20 2012-08-30 Deciphera Pharmaceuticals Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
EP2172462A4 (en) 2007-06-27 2010-12-15 Nissan Chemical Ind Ltd METHOD FOR PRODUCING A 3-HYDROXYPROPAN-1-ON COMPOUND, METHOD FOR PRODUCING A 2-PROPENE-1-ON COMPOUND, AND METHOD FOR PRODUCING AN ISOXAZOLINE COMPOUND
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN114615982A (zh) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 用于治疗胃肠道间质瘤的瑞普替尼
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
CN118948772A (zh) 2019-12-30 2024-11-15 德西费拉制药有限责任公司 1-(4溴-5-(1乙基-7-(甲氨基)-2侧氧基-1,2-二氢-1,6-萘啶-3基)-2氟苯基)-3-苯基脲的组合物
AU2021303146A1 (en) * 2020-06-29 2023-02-02 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.

Also Published As

Publication number Publication date
CZ192397A3 (en) 1997-09-17
CN1175256A (zh) 1998-03-04
MA23753A1 (fr) 1996-07-01
DE69520075T2 (de) 2001-08-02
US5972951A (en) 1999-10-26
PL321048A1 (en) 1997-11-24
TR199501597A2 (tr) 1996-07-21
IL116486A0 (en) 1997-08-14
FI972583A0 (fi) 1997-06-17
HUT77650A (hu) 1998-07-28
MX9704777A (es) 1997-10-31
OA10610A (en) 2002-09-06
AU697361B2 (en) 1998-10-01
SK80297A3 (en) 1998-12-02
NO972910D0 (no) 1997-06-20
BG101715A (bg) 1998-02-27
FI972583L (fi) 1997-08-19
ES2153907T3 (es) 2001-03-16
ATE199085T1 (de) 2001-02-15
EP0799226B1 (en) 2001-02-07
EP0799226A1 (en) 1997-10-08
FI972583A7 (fi) 1997-08-19
NO972910L (no) 1997-08-14
AP757A (en) 1999-09-06
WO1996019477A1 (en) 1996-06-27
AU4343396A (en) 1996-07-10
DZ1957A1 (fr) 2002-02-17
AP9701006A0 (en) 1997-07-31
DE69520075D1 (de) 2001-03-15
JPH10510821A (ja) 1998-10-20
NZ298036A (en) 1998-11-25
BR9510419A (pt) 1998-05-19
BG61977B1 (bg) 1998-11-30
CA2208244A1 (en) 1996-06-27

Similar Documents

Publication Publication Date Title
AR002011A1 (es) Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas.
DK0984966T3 (da) 9-azabicyclo[3.3.1]non-2-en derivater, som er cholinerge ligander på nikotin-ACh receptorer
ES8103744A1 (es) Un metodo para la preparacion de derivados de ftalimidina
IE891797L (en) 4-amino quinolines and naphthyridines, process for their¹preparation and their use as medicines
DE69810958D1 (de) Harnstoffderivate und ihre anwendung als integrin-inhibitoren
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
ATE182889T1 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
AR008291A1 (es) Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento.
ATE218329T1 (de) Anthracyclinon-derivate und ihre verwendung in amyloidose
DK1034174T3 (da) Azaringetherderivater og disses anvendelse som nikotin-ACh-receptormodulatorer
DE69520279D1 (de) Bibphenylamid-derivate als 5-ht1d-antagonisten
ES476863A1 (es) Un procedimiento para la preparacion de nuevos derivados de anilina.
ES2012648A6 (es) Procedimiento para la preparacion de nuevos derivados de 1,4-benzoxazina y 1,4-benzotiazina.
AT389108B (de) Neue pyridazinonderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
PT90912A (pt) Processo para a preparacao de derivados de tiofenol
DE69810107D1 (de) Azacyclooktan- und heptan-derivate, ihre herstellung und ihre therapeutische verwendung
NZ218453A (en) Pharmaceutical compositions containing a synergistic mixture of a dihydropyridine derivative and pyridazodiazepine derivative
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
SE7503868L (sv) Forfarande for framstellning av bensobicyklonenderivat.
DE68907857D1 (de) Beta-d-phenylthioxyloside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE96803T1 (de) Indolo(3,2,1-de>(1,4>-oxazino(2,3,4ij>(1,5>naphthyridinderivate, verfahren zu ihrer herstellung und zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
AU547599B2 (en) Tricyclic compounds
CO4700296A1 (es) Compuestos nuevos para el tratamiento de desordenes del snc y el proceso para su preparacion
ATE17490T1 (de) Dithiino (1,4) (2,3-c) pyrrolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
DE68903893D1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.